Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection - PubMed (original) (raw)
Comparative Study
Residual viral replication during antiretroviral therapy boosts human immunodeficiency virus type 1-specific CD8+ T-cell responses in subjects treated early after infection
Gabriel M Ortiz et al. J Virol. 2002 Jan.
Abstract
Human immunodeficiency virus type 1 (HIV-1)-infected subjects treated early after infection have preserved HIV-1-specific CD4+ T-cell function. We studied the effect of highly active antiretroviral therapy (HAART) on the frequency of HIV-1-specific CD8+ T cells in patients treated during early (n = 31) or chronic (n = 23) infection. The degree of viral suppression and time of initiation of treatment influenced the magnitude of the CD8+ T-cell response. HIV-1-specific CD8+ T cells can increase in number after HAART in subjects treated early after infection who have episodes of transient viremia.
Figures
FIG. 1.
Longitudinal measurements of plasma viral load and HIV-1-specific CD8+ T-cell responses in six subjects with early HIV-1 infection who had at least two viremic episodes per year while on HAART. Total CD8+ T-cell responses are expressed as spot-forming cells (SFC) per million PBMCs and represent the sum of responses against Env, Gag, Pol, and Nef.
FIG. 2.
Box plot comparisons of total HIV-1-specific CD8+ T-cell responses after 1 year of HAART in subjects treated during early or chronic HIV-1 infection who had less than two or two or more viremic episodes per year. Median values are shown within the boxes. Bars, 10th and 90th percentiles; dots, 5th and 95th percentiles. P values were determined by rank-sum t test. SFC, spot-forming cells.
Similar articles
- Impact of antiretroviral therapy and changes in virus load on human immunodeficiency virus (HIV)-specific T cell responses in primary HIV infection.
Lacabaratz-Porret C, Urrutia A, Doisne JM, Goujard C, Deveau C, Dalod M, Meyer L, Rouzioux C, Delfraissy JF, Venet A, Sinet M. Lacabaratz-Porret C, et al. J Infect Dis. 2003 Mar 1;187(5):748-57. doi: 10.1086/368333. Epub 2003 Feb 18. J Infect Dis. 2003. PMID: 12599048 Clinical Trial. - Decay kinetics of human immunodeficiency virus-specific CD8+ T cells in peripheral blood after initiation of highly active antiretroviral therapy.
Casazza JP, Betts MR, Picker LJ, Koup RA. Casazza JP, et al. J Virol. 2001 Jul;75(14):6508-16. doi: 10.1128/JVI.75.14.6508-6516.2001. J Virol. 2001. PMID: 11413318 Free PMC article. - Functional restoration of human immunodeficiency virus and Epstein-Barr virus-specific CD8(+) T cells during highly active antiretroviral therapy is associated with an increase in CD4(+) T cells.
Kostense S, Otto SA, Knol GJ, Manting EH, Nanlohy NM, Jansen C, Lange JM, van Oers MH, Miedema F, van Baarle D. Kostense S, et al. Eur J Immunol. 2002 Apr;32(4):1080-9. doi: 10.1002/1521-4141(200204)32:4<1080::AID-IMMU1080>3.0.CO;2-R. Eur J Immunol. 2002. PMID: 11920575 - Human immunodeficiency virus interactions with CD8+ T lymphocytes.
Saksena NK, Wu JQ, Potter SJ, Wilkinson J, Wang B. Saksena NK, et al. Curr HIV Res. 2008 Jan;6(1):1-9. doi: 10.2174/157016208783572008. Curr HIV Res. 2008. PMID: 18288969 Review. - T cell immunity in acute HIV-1 infection.
Streeck H, Nixon DF. Streeck H, et al. J Infect Dis. 2010 Oct 15;202 Suppl 2(Suppl 2):S302-8. doi: 10.1086/655652. J Infect Dis. 2010. PMID: 20846037 Free PMC article. Review.
Cited by
- Persistent Low-level Viremia While on Antiretroviral Therapy Is an Independent Risk Factor for Virologic Failure.
Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, Deiss R, Okulicz J, Agan BK, Ganesan A. Joya C, et al. Clin Infect Dis. 2019 Nov 27;69(12):2145-2152. doi: 10.1093/cid/ciz129. Clin Infect Dis. 2019. PMID: 30785191 Free PMC article. - Sustained and transient oscillations and chaos induced by delayed antiviral immune response in an immunosuppressive infection model.
Shu H, Wang L, Watmough J. Shu H, et al. J Math Biol. 2014 Jan;68(1-2):477-503. doi: 10.1007/s00285-012-0639-1. Epub 2013 Jan 11. J Math Biol. 2014. PMID: 23306425 - Influence of episodes of intermittent viremia ("blips") on immune responses and viral load rebound in successfully treated HIV-infected patients.
Castro P, Plana M, González R, López A, Vilella A, Nicolas JM, Gallart T, Pumarola T, Bayas JM, Gatell JM, García F. Castro P, et al. AIDS Res Hum Retroviruses. 2013 Jan;29(1):68-76. doi: 10.1089/AID.2012.0145. Epub 2012 Dec 16. AIDS Res Hum Retroviruses. 2013. PMID: 23121249 Free PMC article. Clinical Trial. - Characterization of peripheral and mucosal immune responses in rhesus macaques on long-term tenofovir and emtricitabine combination antiretroviral therapy.
Jasny E, Geer S, Frank I, Vagenas P, Aravantinou M, Salazar AM, Lifson JD, Piatak M Jr, Gettie A, Blanchard JL, Robbiani M. Jasny E, et al. J Acquir Immune Defic Syndr. 2012 Dec 1;61(4):425-35. doi: 10.1097/QAI.0b013e318266be53. J Acquir Immune Defic Syndr. 2012. PMID: 22820802 Free PMC article. - Persistence of genital tract T cell responses in HIV-infected women on highly active antiretroviral therapy.
Mkhize NN, Gumbi PP, Liebenberg LJ, Ren Y, Smith P, Denny L, Passmore JA. Mkhize NN, et al. J Virol. 2010 Oct;84(20):10765-72. doi: 10.1128/JVI.00518-10. Epub 2010 Aug 4. J Virol. 2010. PMID: 20686039 Free PMC article.
References
- Allen, T. M., D. H. O’Connor, P. Jing, J. L. Dzuris, B. R. Mothe, T. U. Vogel, E. Dunphy, M. E. Liebl, C. Emerson, N. Wilson, K. J. Kunstman, X. Wang, D. B. Allison, A. L. Hughes, R. C. Desrosiers, J. D. Altman, S. M. Wolinsky, A. Sette, and D. I. Watkins. 2000. Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 407:386–390. - PubMed
- Altfeld, M., E. S. Rosenberg, R. Shankarappa, J. S. Mukherjee, F. M. Hecht, R. L. Eldridge, M. M. Addo, S. H. Poon, M. N. Phillips, G. K. Robbins, P. E. Sax, S. Boswell, J. O. Kahn, C. Brander, P. J. Goulder, J. A. Levy, J. I. Mullins, and B. D. Walker. 2001. Cellular immune responses and viral diversity in individuals treated during acute and early HIV-1 infection. J. Exp. Med. 193:169–180. - PMC - PubMed
- Appay, V., D. F. Nixon, S. M. Donahoe, G. M. Gillespie, T. Dong, A. King, G. S. Ogg, H. M. Spiegel, C. Conlon, C. A. Spina, D. V. Havlir, D. D. Richman, A. Waters, P. Easterbrook, A. J. McMichael, and S. L. Rowland-Jones. 2000. HIV-specific CD8+ T cells produce antiviral cytokines but are impaired in cytolytic function. J. Exp. Med. 192:63–76. - PMC - PubMed
- Autran, B., G. Carcelain, T. Li, C. Blanc, D. Mathez, R. Tubiana, C. Katlama, P. Debre, and J. Leibowitch. 1997. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 277:112–116. - PubMed
- Champagne, P., G. S. Ogg, A. S. King, C. Knabenhans, K. Ellefsen, M. Nobile, V. Appay, G. P. Rizzardi, S. Fleury, M. Lipp, R. Forster, S. Rowland-Jones, R. P. Sekaly, A. J. McMichael, and G. Pantaleo. 2001. Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410:106–111. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
- M01 RR000102/RR/NCRR NIH HHS/United States
- MO1-RR00102/RR/NCRR NIH HHS/United States
- F31 GM20068-01/GM/NIGMS NIH HHS/United States
- R01 AI044595/AI/NIAID NIH HHS/United States
- U01 AI041534/AI/NIAID NIH HHS/United States
- R37 AI036082/AI/NIAID NIH HHS/United States
- R37 AI36082/AI/NIAID NIH HHS/United States
- F31 GM020068/GM/NIGMS NIH HHS/United States
- U01AI41534/AI/NIAID NIH HHS/United States
- R01 AI44595/AI/NIAID NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials